Journal of Infection and Public Health
Volume 2, Issue 3 , Pages 141-146 , 2009

Improvement in vancomycin utilization in adults in a Saudi Arabian Medical Center using the Hospital Infection Control Practices Advisory Committee guidelines and simple educational activity

  • Jean G. Dib

      Affiliations

    • Pharmacy Services Division, Saudi Aramco Medical Services Organization (SAMSO), Saudi Aramco, Saudi Arabia
    • ,
  • Jaffar A. Al-Tawfiq

      Affiliations

    • Internal Medicine Services Division, Saudi Aramco Medical Services Organization (SAMSO), Saudi Aramco, Saudi Arabia
    • Corresponding Author InformationCorresponding author at: P.O. Box 76, Rm A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia. Tel.: +966 3 877 3524; fax: +966 3 877 3790.
    • ,
  • Saud Al Abdulmohsin

      Affiliations

    • Pharmacy Services Division, Saudi Aramco Medical Services Organization (SAMSO), Saudi Aramco, Saudi Arabia
    • ,
  • Khurram Mohammed

      Affiliations

    • Pharmacy Services Division, Saudi Aramco Medical Services Organization (SAMSO), Saudi Aramco, Saudi Arabia
    • ,
  • Phyllis D. Jenden

      Affiliations

    • Pharmacy Services Division, Saudi Aramco Medical Services Organization (SAMSO), Saudi Aramco, Saudi Arabia

Received 16 February 2009 ,Revised 30 June 2009 ,Accepted 2 July 2009.

References 

  1. Center for Disease Control and Prevention . Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbid Mortal Wkly Rep. 1995;44(RR-12):1–13
  2. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs. 1996;51(Suppl. 1):6–12
  3. Jevons MP. Celbenin resistant staphylococci. Br Med J. 1961;1:124–125
  4. Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J. 2000;19:1163–1166
  5. Center for Disease Control and Prevention . Four pediatric deaths from community-acquired methicillin resistant Staphylococcus aureus—Minnesota and North Dakota, 1997–1999. Morbid Mortal Wkly Rep. 1999;48:707–710
  6. Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211–215
  7. Center for Disease Control and Prevention. Healthcare-Associated Methicillin Resistant Staphylococcus aureus (MRSA): Data & Statistics for Healthcare-Associated MRSA. http://www.cdc.gov/ncidod/dhqp/ar_mrsa_data.html. Accessed on March 18, 2006.
  8. Christenson JC, Korgenski EK, Jenkins E, Daly JA. Detection of vancomycin-resistant enterococci colonization in a children's hospital. Am J Infect Control. 1998;26(6):569–571
  9. Center for Disease Control and Prevention . Staphylococcus aureus with reduced susceptibility to vancomycin. Morbid Mortal Wkly Rep. 1997;46:765–766
  10. Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O’Gara PT, et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(August (8)):676–685
  11. Al-Tawfiq JA. Incidence and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in a Saudi Arabian Hospital 1999–2003. Infect Control Hosp Epidemiol. 2006;27:1137–1139
  12. Cockcroft D. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  13. Askarian M, Assadian O, Safaee G, Golkar A, Namazi S, Movahed MR. Vancomycin use in a large teaching hospital in Shiraz, Islamic Republic of Iran 2003. East Mediterr Health J. 2007;13(September–October (5)):1195–1201
  14. Johnson SV, Hoey LL, Vace-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy. 1995;15:579–585
  15. Evans ME, Kortes KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol. 1996;17:356–359
  16. Drinkovic D, Taylor SL, Pottumarthy S, Morris AJ. Prospective vancomycin audit in Auckland healthcare hospitals. N Z Med J. 1999;112:336–339
  17. You JH, Lyon DJ, Lee BS, Kwan SM, Tang HY. Vancomycin utilization at a teaching hospital in Hong Kong. Am J Health-Syst Pharm. 2001;58:2167–2169
  18. Wright SW, Wrenn KD. Appropriateness of vancomycin use in the emergency department. Ann Emerg Med. 1998;32(5):531–536
  19. Junior MS, Correa L, Marra AR, Camargo LF, Pereira CA. Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study. BMC Infect Dis. 2007;7(August):88
  20. Hamilton CD, Drew R, Janning SW, Latour JK, Hayward S. Excessive use of vancomycin: a successful intervention strategy at an academic medical center. Infect Control Hosp Epidemiol. 2000;21(January (1)):42–45
  21. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(January (1)):82–98
  22. No author listed. Vancomycin dosing and monitoring. Med Lett Drugs Ther 2009;51(1309):25.

PII: S1876-0341(09)00052-5

doi: 10.1016/j.jiph.2009.07.002

Journal of Infection and Public Health
Volume 2, Issue 3 , Pages 141-146 , 2009

Article Tools